Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Miraculins Inc.

www.miraculins.com

Latest From Miraculins Inc.

Deals In Depth: June/July 2013

In a regional deal, AstraZeneca licensed rights to FibroGen’s renal candidate in an alliance worth $815 million; Elan finally agreed to an $8.3 billion takeover by Perrigo; biopharma financing totaled $7.1 billion and $2 billion in June and July, respectively, while device fundraising reached $325 million and $316 million in the same months.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, September 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Medical Device Deals Update, August 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity.

Medical Device

Device/Diagnostics Quarterly Deal Statistics, Q1 2013

Device companies kicked off 2013 by raising $1.1 billion via 45 transactions; the only device M&A transaction in Q1 to exceed the billion-dollar mark was Cardinal Health Inc.’s $2.07 billion acquisition of AssuraMed. Diagnostics firms began 2013 by raising a total of $286 million in the opening quarter, a 46% improvement over Q4 2012’s tally.

Medical Device Deals
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Miraculins Inc.
  • Senior Management
  • Christopher J Moreau, Pres. & CEO
    James Kinley, CFO
    L. Michael Coutts, Dir., Bus. Dev.
    Paul Moreau, VP, Sales & Mktg.
  • Contact Info
  • Miraculins Inc.
    Phone: (204) 453-1408
    6-1250 Waverly St.
    Winnepeg, R3T 6C6
    Canada
Advertisement
Advertisement
UsernamePublicRestriction

Register